Home › Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for...
 

Keywords :   


Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for...

2014-09-16 12:26:38| Chemicals - Topix.net

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer who have rising Prostate Specific Antigen levels and no detectable metastases.

Tags: iii begin trial phase

Category:Chemicals

Latest from this category

All news
05.11BASF Opens New Production Line in Heerenveen, the Netherlands
05.11Registration Now Open for RadTech 2025
05.11Teknos Poland Honored by Farby i Lakiery
05.11Durable Floor Coating from HMG Paints Transforms FC United\'s SMRE Bar
04.11Registration Open for 2025 Waterborne Symposium
04.11ROSS Ribbon Blenders Provide Safe, Efficient Bulk Blending
04.11U.S. Green Building Council Announces 2024 Leadership Award Recipients
04.11ASTM International Publishes New Standards for FT4 Powder Rheometer Procedures
Chemicals »
06.11Atlantic Tropical Weather Outlook
06.11Tropical Storm Rafael Graphics
06.11Tropical Storm Rafael Public Advisory Number 9A
06.11Summary for Tropical Storm Rafael (AT3/AL182024)
06.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
More »